FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295786669> ?p ?o ?g. }

• W4295786669 endingPage "654" @default.
• W4295786669 startingPage "645" @default.
• W4295786669 abstract "<b><i>Introduction:</i></b> Adverse events (AEs) of urinary protein from monoclonal antibodies against vascular endothelial growth factor are factors that often inhibit systemic therapy for unresectable hepatocellular carcinoma (uHCC). This study aimed to elucidate risk factors of urinary protein in the early period (&#x3c;12 weeks) of atezolizumab plus bevacizumab treatment (Atez/Bev). <b><i>Methods:</i></b> From 2020 to June 2022, 193 uHCC patients treated with Atez/Bev at our affiliated hospitals were enrolled (median 73 years, 158 males, 183 Child-Pugh A, BCLC-0:A:B:C = 1:7:73:112). AEs related to urinary protein (≥G2) within 12 weeks were defined as significant, and related clinical features were analyzed retrospectively. <b><i>Results:</i></b> In analyses of risk factors of urinary protein-related AEs during the first 12 weeks after starting Atez/Bev using a logistic regression method, univariate analysis showed positive for hypertension (odds ratio [OR] 3.54, 95% CI: 1.28–9.80, <i>p</i> = 0.015) and baseline urinary protein and urine creatinine ratio (UPC: ≥0.16) (OR: 2.52, 95% CI: 1.09–5.83, <i>p</i> = 0.031) as pretreatment clinical factors, while elevation of urinary protein in the early period (baseline to 3 weeks) with delta UPC per 3 weeks (ΔUPC/3W) (≥0.23) (OR: 15.80, 95% CI: 6.15–40.50, <i>p</i> &#x3c; 0.001) was a clinical factor after starting treatment. Multivariate analysis of only baseline clinical factors revealed positive for history of hypertension as the only predictive factor (OR: 3.20, 95% CI: 1.14–8.95, <i>p</i> = 0.027), while only ΔUPC/3W (≥0.23) (OR: 14.40, 95% CI: 4.91–42.00, <i>p</i> &#x3c; 0.001) were noted in multivariate analysis including ΔUPC/3W. Predictive factors for ΔUPC/3W (≥0.23) were hypertension (OR: 3.50, 95% CI: 1.23–99.90, <i>p</i> = 0.019) and UPC (≥0.16) (OR: 6.12, 95% CI: 2.61–14.30, <i>p</i> &#x3c; 0.001) in multiple analysis. <b><i>Discussion/Conclusion:</i></b> Urinary protein-related AEs are frequently observed during Atez/Bev treatment in uHCC patients with elevated ΔUPC/3W (≥0.23), and ΔUPC/3W (≥0.23) is often seen in patients with hypertension and/or UPC (≥0.16)." @default.
• W4295786669 created "2022-09-15" @default.
• W4295786669 creator A5007665821 @default.
• W4295786669 creator A5008593372 @default.
• W4295786669 creator A5009103376 @default.
• W4295786669 creator A5013902375 @default.
• W4295786669 creator A5015404124 @default.
• W4295786669 creator A5015534419 @default.
• W4295786669 creator A5017999006 @default.
• W4295786669 creator A5020047441 @default.
• W4295786669 creator A5022551435 @default.
• W4295786669 creator A5023981784 @default.
• W4295786669 creator A5025980433 @default.
• W4295786669 creator A5026964230 @default.
• W4295786669 creator A5028697785 @default.
• W4295786669 creator A5030286729 @default.
• W4295786669 creator A5030669902 @default.
• W4295786669 creator A5032900701 @default.
• W4295786669 creator A5035134420 @default.
• W4295786669 creator A5035561731 @default.
• W4295786669 creator A5040485741 @default.
• W4295786669 creator A5043762552 @default.
• W4295786669 creator A5047345098 @default.
• W4295786669 creator A5049568375 @default.
• W4295786669 creator A5050706722 @default.
• W4295786669 creator A5053874442 @default.
• W4295786669 creator A5059536902 @default.
• W4295786669 creator A5061999363 @default.
• W4295786669 creator A5064418329 @default.
• W4295786669 creator A5064709438 @default.
• W4295786669 creator A5066413780 @default.
• W4295786669 creator A5068214058 @default.
• W4295786669 creator A5072760293 @default.
• W4295786669 creator A5073095975 @default.
• W4295786669 creator A5078450345 @default.
• W4295786669 creator A5080709934 @default.
• W4295786669 creator A5083997418 @default.
• W4295786669 creator A5085648916 @default.
• W4295786669 creator A5085777607 @default.
• W4295786669 creator A5088307695 @default.
• W4295786669 creator A5090570708 @default.
• W4295786669 creator A5090674063 @default.
• W4295786669 date "2022-01-01" @default.
• W4295786669 modified "2023-10-18" @default.
• W4295786669 title "Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma" @default.
• W4295786669 doi "https://doi.org/10.1159/000526521" @default.
• W4295786669 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36103846" @default.
• W4295786669 hasPublicationYear "2022" @default.
• W4295786669 type Work @default.
• W4295786669 citedByCount "3" @default.
• W4295786669 countsByYear W42957866692022 @default.
• W4295786669 countsByYear W42957866692023 @default.
• W4295786669 crossrefType "journal-article" @default.
• W4295786669 hasAuthorship W4295786669A5007665821 @default.
• W4295786669 hasAuthorship W4295786669A5008593372 @default.
• W4295786669 hasAuthorship W4295786669A5009103376 @default.
• W4295786669 hasAuthorship W4295786669A5013902375 @default.
• W4295786669 hasAuthorship W4295786669A5015404124 @default.
• W4295786669 hasAuthorship W4295786669A5015534419 @default.
• W4295786669 hasAuthorship W4295786669A5017999006 @default.
• W4295786669 hasAuthorship W4295786669A5020047441 @default.
• W4295786669 hasAuthorship W4295786669A5022551435 @default.
• W4295786669 hasAuthorship W4295786669A5023981784 @default.
• W4295786669 hasAuthorship W4295786669A5025980433 @default.
• W4295786669 hasAuthorship W4295786669A5026964230 @default.
• W4295786669 hasAuthorship W4295786669A5028697785 @default.
• W4295786669 hasAuthorship W4295786669A5030286729 @default.
• W4295786669 hasAuthorship W4295786669A5030669902 @default.
• W4295786669 hasAuthorship W4295786669A5032900701 @default.
• W4295786669 hasAuthorship W4295786669A5035134420 @default.
• W4295786669 hasAuthorship W4295786669A5035561731 @default.
• W4295786669 hasAuthorship W4295786669A5040485741 @default.
• W4295786669 hasAuthorship W4295786669A5043762552 @default.
• W4295786669 hasAuthorship W4295786669A5047345098 @default.
• W4295786669 hasAuthorship W4295786669A5049568375 @default.
• W4295786669 hasAuthorship W4295786669A5050706722 @default.
• W4295786669 hasAuthorship W4295786669A5053874442 @default.
• W4295786669 hasAuthorship W4295786669A5059536902 @default.
• W4295786669 hasAuthorship W4295786669A5061999363 @default.
• W4295786669 hasAuthorship W4295786669A5064418329 @default.
• W4295786669 hasAuthorship W4295786669A5064709438 @default.
• W4295786669 hasAuthorship W4295786669A5066413780 @default.
• W4295786669 hasAuthorship W4295786669A5068214058 @default.
• W4295786669 hasAuthorship W4295786669A5072760293 @default.
• W4295786669 hasAuthorship W4295786669A5073095975 @default.
• W4295786669 hasAuthorship W4295786669A5078450345 @default.
• W4295786669 hasAuthorship W4295786669A5080709934 @default.
• W4295786669 hasAuthorship W4295786669A5083997418 @default.
• W4295786669 hasAuthorship W4295786669A5085648916 @default.
• W4295786669 hasAuthorship W4295786669A5085777607 @default.
• W4295786669 hasAuthorship W4295786669A5088307695 @default.
• W4295786669 hasAuthorship W4295786669A5090570708 @default.
• W4295786669 hasAuthorship W4295786669A5090674063 @default.
• W4295786669 hasConcept C121608353 @default.
• W4295786669 hasConcept C126322002 @default.
• W4295786669 hasConcept C126894567 @default.
• W4295786669 hasConcept C144301174 @default.
• W4295786669 hasConcept C156957248 @default.

• next